Zeitschrift für Phytotherapie 2013; 34(06): 274-278
DOI: 10.1055/s-0033-1349778
Praxis
CED
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Phytotherapie bei chronisch entzündlichen Darmerkrankungen

Jost Langhorst

Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. Januar 2014 (online)

Zusammenfassung

Etwa jeder vierte Patient mit einer chronisch entzündlichen Darmerkrankung (CED) in Deutschland berichtet über eigene Erfahrungen mit dem komplementären Einsatz von Phytotherapeutika aufgrund seiner CED. Nur für wenige Präparate liegen bisher klinische Studien für diese Indikation vor, sie werden hier vorgestellt. Im klinischen Alltag haben v.a. Flohsamen, Myrrhe, Kamille und Kaffeekohle, Weihrauch oder Heidelbeeren Bedeutung. In den deutschen AWMF-S3-Leitlinien für die Therapie der Colitis ulcerosa werden Flohsamen und Curcumin als Therapieoptionen genannt.

Summary

Phytotherapy for chronic inflammatory bowel disease

More than 50% of patients with inflammatory bowel disease (IBD) in Germany report own experience with CAM treatment modalities. Approximately every forth patient has experience with the complementary use of herbal treatment. Clinical trials have been performed with a variety of herbal preparations which are introduced in this paper. In the daily routine of patient care the use of psyllium, frankincense, a combination of myrrh, chamomile and coffee charcoal or bilberry is of importance. In the German AWMF guidelines for ulcerative colitis, psyllium and curcumin have been added as treatment option for maintaining remission.

 
  • Literatur

  • 1 Ben-Arye E, Goldin E, Wengrower D et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002; 37: 444-449
  • 2 Biedermann L, Mwinyi J, Scharl M et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – an open pilot study. J Crohns Colitis 2013; 7: 271-279
  • 3 Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433
  • 4 Gerhardt H, Seifert F, Buvari P et al. Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15. Z Gastroenterol 2001; 39: 11-17
  • 5 Gupta I, Parihar A, Malhotra P et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997; 2: 37-43
  • 6 Gupta I, Parihar A, Malhotra P et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001; 67: 391-395
  • 7 Hanai H, Iida T, Takeuchi K et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506
  • 8 Holtmeier W, Zeuzem S, Preiss J et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy.. Inflamm Bowel Dis 2011; 17: 573-582
  • 9 Huber R, Ditfurth AV, Amann F et al. Tormentil for active ulcerative colitis: an openlabel, dose-escalating study. J Clin Gastroenterol 2007; 41: 834-838
  • 10 Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease – a controlled clinical trial. Phytomedicine 2010; 17: 305-309
  • 11 Langhorst J. Gastrointestinale Erkrankungen: Chronisch entzündliche Darmerkrankungen. In: Dobos G, Deuse U, Michalsen A. Chronische Erkrankungen integrativ. München: Elsevier, Urban & Fischer; 2006
  • 12 Langhorst J, Anthonisen IB, Steder-Neukamm U et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med 2007; 15: 30-37
  • 13 Langhorst J, Anthonisen IB, Steder-Neukamm U et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in German patients with inflammatory bowel disease: Results from a national survey. Inflamm Bowel Dis 2005; 11: 287-295
  • 14 Langhorst J, Varnhagen I, Schneider SB et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared to mesalazine in maintaining remission in ulcerative colitis – a doubleblind, double-dummy study. Aliment Pharmacol Ther 2013; 38: 490-500
  • 15 Langmead L, Feakins RM, Goldthorpe S et al. Randomized, double-blind, placebo-controlled trial of oral Aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 739-747
  • 16 Naftali T, Bar-Lev SchleiderL, Dotan I et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013; 11: 1276-1280
  • 17 Naftali T, Lev LB, Yablecovitch D et al. Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 2011; 13: 455-458
  • 18 Omer B, Krebs S, Omer H, Noor TO. Steroidsparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 2007; 14: 87-95